Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 208

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 208
---
.

<div align='center'>121

DESCRIPTION OF THE SECURITIES WE ARE OFFERING</div>

Ordinary Shares

The material terms and provisions
of our Ordinary Shares are described under the caption “Description of Share Capital” in this prospectus.

<div align='center'>SHARES ELIGIBLE FOR FUTURE SALE</div>

Prior to this offering, no
public market existed for our Ordinary Shares. Sales of substantial amounts of our Ordinary Shares following this offering, or the perception
that these sales could occur, could adversely affect prevailing market prices of our Ordinary Shares and could impair our future ability
to obtain capital, especially through an offering of equity securities. Assuming that the underwriters do not exercise in full their option
to purchase additional Ordinary Shares and/or additional Warrants with respect to this offering and assuming no exercise of options outstanding
following this offering, we will have an aggregate of Ordinary Shares outstanding upon the closing of this offering. Of these shares,
the Ordinary Shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act,
unless purchased by “affiliates” (as that term is defined under Rule 144 of the Securities Act, or Rule 144), who
may sell only the volume of shares described below and whose sales would be subject to additional restrictions described below.

The remaining Ordinary Shares
will be held by our existing shareholders and will be deemed to be “restricted securities” under Rule 144. Subject to
certain contractual restrictions, including the lock-up agreements described below, restricted securities may only be sold in the public
market pursuant to an effective registration statement under the Securities Act or pursuant to an exemption from registration under Rule 144,
Rule 701 or Rule 904 under the Securities Act. These rules are summarized below. Sales of these shares in the public market
after the restrictions under the lock-up agreements lapse, or the perception that those sales may occur, could cause the prevailing market
price of our Ordinary Shares to decrease or to be lower than it might be in the absence of those sales or perceptions.

Eligibility of Restricted Shares for Sale in the Public Market

Approximately 3,929,378 of
our Ordinary Shares will be eligible for resale pursuant to Rule 144 after 90 days following the pricing of this offering as
follows:

| ● | with respect to non-affiliates of our company who will hold an aggregate of 2,137,322 Ordinary Shares upon the consummation of this offering, following the expiration of a non